MedCityNews.com has partnered with MidAmerica Healthcare Venture Forum, the showcase that offers the “Best of the Midwest,” to highlight the increasing role the Midwest plays in bringing the latest technology and emerging innovations to the investment community. This event, held in association with Mid-America Healthcare Investors Network (MHIN), will take place April 22-23, 2014 in Chicago.
Now in its 11th year, MidAmerica Healthcare Venture Forum unites active healthcare venture capitalists and corporate business development executives with more than 30 of the most promising Midwest-based healthcare startups to facilitate investment opportunities and showcase dealflow originating in the Midwest.
Join us April 22-23 to hear from thought leaders, prominent industry players and startup companies spanning the medical device, biopharmaceuticals, regenerative medicine, agri-health, diagnostics, health IT and industrial biotech sectors.
The program consists of sessions that include: Mobile and the Path to FDA Approval: Best Practices and Success; State of Venture Capital and Investing Panel; and a special session on Crowdfunding and the Jobs Act in Healthcare. There will also be an announcement on new Midwest investing research.
Early-stage startups located in the Midwest may apply to present in the Company Showcase. We are accepting 30 companies and the deadline is January 30. Companies that meet the criteria should apply now. To attend the event, register now. Our Extreme Early Bird pricing ends February 2.
I encourage you to make plans now to join the best of the Midwest’s healthcare venture capital and startup communities at MidAmerica Healthcare Venture Forum — the destination healthcare investing conference in the Midwest.
For the best return on your investment, reserve your place now. For just three more weeks you’ll save $300 and get our very best rate.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Who should attend MidAmerica Healthcare Venture Forum?
- C-level executives from healthcare startups
- Venture capitalists, angel investors and investment bankers
- Corporate business development executives and R&D officers
- Tech transfer officers, incubators and healthcare consultants
This conference is a national event, and not to be missed by anyone interested in knowing the trends and up-and-coming startups in healthcare and the life sciences.
